Skip to content


More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro® to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression. 

Starting therapy early may have huge benefits when we project forward another 10 or 20 years. I believe this device is helping me save vision for many people.

Jacob Olding, OD Jacob Olding, OD

AdaptDx has really helped me care for my patients. It has helped me find macular degeneration a lot earlier and be able to proactively treat my patients.

Laurie Sorrenson, OD, FAAO Laurie Sorrenson, OD, FAAO

In the first few months of using the AdaptDx, we've more than doubled our nutraceutical sales and have seen a sizable increase in optical sales associated with UV and blue light blocking protection.

R. Aaron Werner Aaron Werner, OD

The marketing package MacuLogix provides to their customers is the best I have seen with any equipment company!

dr-christa-1-300x4002 Christa Walling, OD

AdaptDx may help you find macular degeneration at least three years before you actually see any clinical signs. Do you want to wait to diagnose glaucoma until someone has a vision-threatening visual field loss? No, you don’t. And we should be thinking the same way about AMD. Let’s find it in its earliest stage so that we can do something about it and try to prevent the bad outcomes.

Jeffry Gerson Headshot Jeffry Gerson, OD, FAAO

The MacuLogix team gives superior installation, education, and support than any ophthalmologic instrument that I can think of. By discussing and identifying your personal practice flow, recommendations and support will be given to best start making this a reflex to discuss with patients and perform in your office on a daily basis.

AmandaLegge_OD Amanda Legge, OD

Since implementing the AMD Excellence Program and performing AdaptDx Pro Rapid Tests on every patient over 60, I can confirm that the studies are true: 25-30% of my patients are failing. By practicing this way, I can confidently say I have more AMD patients than glaucoma and diabetic retinopathy combined, and it will only continue to grow. Luckily, our team is up to the challenge and is excited to contribute to an improved standard of AMD care for our patients!

AmandaLegge_OD Amanda Legge, OD